产品详情
| Name | Sequence | Quantity | Price(2mg)¥ | Price(5mg)¥ |
| c(RGDfC) | c(RGDfC) | 97% | 500 | 800 |
| c(RGDfK) | c(RGDfK) | 97% | 500 | 800 |
| c(RGDyC) | c(RGDyC) | 97% | 500 | 800 |
| c(RGDKC) | c(RGDKC) | 97% | 500 | 800 |
| iRGD | c(CRGDKGPDC) | 97% | 1000 | 1500 |
| 3Flag | DYKDDDDKGDYKDDDDKIDYKDDDDK | 97% | 500 | 1100 |
| Gastrin 1, human | Pyr-GPWLEEEEEAYGWMDF-CONH2 | 97% | 500 | 900 |
| HIV-1 TAT Protein Peptide | NH2-YGRKKRRQRRR-COOH | 97% | 300 | 700 |
| ß-Amyloid (25-35) | NH2-GSNKGAIIGLM-COOH | 97% | 300 | 700 |
| MOG35-55 | MEVGWYRSPFSRVVHLYRNGK | 97% | 500 | 1100 |
| α-MSH | Ac-SYSMEHFRWGKPV-CONH2 | 97% | 300 | 700 |
| Angiopep-2 | NH2-TFFYGGSRGKRNNFKTEEY-COOH | 97% | 500 | 1100 |
| β-Amyloid (1-28) | DAEFRHDSGYEVHHQKLVFFAEDVGSNK | 97% | 1300 | 1600 |
| β-Amyloid (1-40) | DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV | 95% | 2000 | 3000 |
| β-Amyloid (25-35) | GSNKGAIIGLM | 97% | 500 | 900 |
| β-Amyloid (1-42), rat | DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVVIA | 95% | 3500 | 5000 |
| β-Amyloid (1-42), human | DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA | 95% | 3500 | 5000 |
| LL-37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | 95% | 1650 | 2000 |
| Angiotensin I Converting Enzyme Inhibitor | RPGFSPFR | 97% | 500 | 700 |
| Angiotensin Converting Enzyme Inhibitor | Glp-WPRPQIPP | 97% | 500 | 700 |
| Acetalin-3 | Ac-RFMWMK-NH2 | 97% | 500 | 700 |
| Acetalin-2 | Ac-RFMWMR-NH2 | 97% | 500 | 700 |
| Acetalin-1 | Ac-RFMWMT-NH2 | 97% | 500 | 700 |
| ACTH (18-39), human | RPVKVYPNGAEDESAEAFPLEF | 97% | 500 | 1100 |
| ACTH (6-24), human | HFRWGKPVGKKRRPVKVYP | 97% | 500 | 1100 |
| ACTH (4-10), human | MEHFRWG | 97% | 300 | 500 |
| ACTH (4-11), human | MEHFRWGK | 97% | 300 | 500 |
| ACTH (1-10), human | SYSMEHFRWG | 97% | 500 | 700 |
| ACTH (1-13), human | SYSMEHFRWGKPV | 97% | 500 | 700 |
| ACTH (1-16), human | SYSMEHFRWGKPVGKK | 97% | 500 | 700 |
| ACTH (1-17), human | SYSMEHFRWGKPVGKKR | 97% | 500 | 700 |
| ACTH (1-24), human | SYSMEHFRWGKPVGKKRRPVKVYP | 97% | 500 | 1100 |
| ACTH (1-39), human | SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF | 97% | 1800 | 2000 |
| ACTH (1-39), rat | SYSMEHFRWGKPVGKKRRPVKVYPNVAENESAEAFPLEF | 97% | 1800 | 2000 |
| N-Acetyl, ACTH (1-17), human | Ac-SYSMEHFRWGKPVGKKR | 97% | 800 | 1000 |
| Pro-Adrenomedullin (N-20), rat | ARLDTSSQFRKKWNKWALSR-NH2 | 97% | 850 | 1000 |
| Pro-Adrenomedullin (N-20), porcine | ARLDVAAEFRKKWNKWALSR-NH2 | 97% | 850 | 1000 |
| Pro-Adrenomedullin (N-20), human | ARLDVASEFRKKWNKWALSR-NH2 | 97% | 850 | 1000 |
| Adrenomedullin (22-52), human | TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH2 | 97% | 1300 | 1500 |
| Adrenomedullin (1-12), human | YRQSMNNFQGLR | 97% | 500 | 700 |
| Allatostatins/Allatostatin I | APSGAQRLYGFGL-NH2 | 97% | 500 | 700 |
| Allatostatin IV | DRLYSFGL-NH2 | 97% | 500 | 700 |
| Allatostatin II | GDGRLYAFGL-NH2 | 97% | 500 | 700 |
| Allatostatin III | GGSLYSFGL-NH2 | 97% | 500 | 700 |
| Magainin Spacer Peptide | DAEAVGPEAFADQDLDEREVR | 97% | 800 | 1000 |
| Histatin 5 | DSHAKRHHGYKRKFHEKHHSHRGY | 97% | 1000 | 1200 |
| Indolicidin | ILPWKWPWWPWRR-NH2 | 97% | 500 | 700 |
| Angiotensin III, human | RVYIHPF | 97% | 500 | 700 |
| Angiotensin II, human | DRVYIHPF | 97% | 500 | 700 |
| Angiotensin I, human | DRVYIHPFHL | 97% | 500 | 700 |
| CD36 Peptide P (139-155) | CNLAVAAASHIYQNQFVQ | 97% | 800 | 1000 |
| Angiotensin II Antipeptide | EGVYVHPV | 97% | 500 | 700 |
| Angiotensin II (5-8), human | IHPF | 97% | 500 | 700 |
| CD36 Peptide P (93-110) | YRVRFLAKENVTQDAEDNC | 97% | 800 | 1000 |
| Biotinyl-Angiotensin I | Biotin-DRVYIHPFHL | 97% | 800 | 1000 |
| Fibrinogen-Binding Peptide | EHIPA | 97% | 500 | 700 |
| Anti-Inflammatory Peptide 1 | MQMKKVLDS | 97% | 500 | 700 |
| Cecropin P1, porcine | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | 97% | 1400 | 1600 |
| Cecropin A-melittin hybrid peptide [CA(1-7)M(2-9)NH2] | KWKLFKKIGAVLKVL-NH2 | 97% | 700 | 900 |
| Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | 97% | 1000 | 1200 |
| Magainin I | GIGKFLHSAGKFGKAFVGEIMKS | 97% | 1000 | 1200 |
| Lactoferricin, bovine, (BLFC) | RRWQWRMKKLG | 97% | 500 | 700 |
| Apelin-13, human, bovine | QRPRLSHKGPMPF | 97% | 500 | 700 |
| (Glp1)-Apelin-13, human, bovine | Glp-RPRLSHKGPMPF | 97% | 500 | 700 |
| α-Bag Cell Peptide (1-7) | APRLRFY | 97% | 500 | 700 |
| α-Bag Cell Peptide (1-8) | APRLRFYS | 97% | 500 | 700 |
| α-Bag Cell Peptide (1-9) | APRLRFYSL | 97% | 500 | 700 |
| γ-Bag Cell Factor | RLRFD | 97% | 500 | 700 |
| β-Bag Cell Factor | RLRFH | 97% | 500 | 700 |
| β-Amyloid (1-14) | DAEFRHDSGYEVHH | 97% | 500 | 700 |
| β-Amyloid (1-13) | DAEFRHDSGYEVH | 97% | 500 | 700 |
| β-Amyloid (1-12) | DAEFRHDSGYEV | 97% | 500 | 700 |
| β-Amyloid (1-11) | DAEFRHDSGYE | 97% | 500 | 700 |
| β-Amyloid (1-10) | DAEFRHDSGY | 97% | 500 | 700 |
| β-Amyloid (1-9) | DAEFRHDSG | 97% | 500 | 700 |
| β-Amyloid (1-20) | DAEFRHDSGYEVHHQKLVFF | 97% | 850 | 1000 |
| β-Amyloid (1-18) | DAEFRHDSGYEVHHQKLV | 97% | 850 | 1000 |
| Bombesin | Glp-QRLGNQWAVGHLM-NH2 | 97% | 850 | 1000 |
| Osteocalcin (37-49), human | GFQEAYRRFYGPV | 97% | 850 | 1000 |
| Myelopeptide-2 (MP-2) | LVVYPW | 97% | 500 | 700 |
| Bone Gla Protein (45-49) | FYGPV | 97% | 500 | 700 |
| [Tyr38, Phe42,46] Bone Gla Protein | YQEAFRRFFGPV | 97% | 500 | 700 |
| [Tyr0] Bradykinin | YRPPGFSPFR | 97% | 500 | 700 |
| Bradykinin | RPPGFSPFR | 97% | 500 | 700 |
| [Thi5,8,DPhe7] Bradykinin | RPPG-Thi-S-DPhe-Thi-R | 97% | 500 | 800 |
| CART (55-76), rat | IPIYEKKYGQVPMCDAGEQCAV(Cys14&Cys20 bridge) | 97% | 850 | 1100 |
| Cholecystokinin, CCK Tetrapeptide (30-33) | WMDF-NH2 | 97% | 500 | 700 |
| Cholecystokinin, CCK Octapeptide (26-33), Non-Sulfated form | DYMGWMDF-NH2 | 97% | 500 | 700 |
| Katacalcin | DMSSDLERDHRPHVSMPQNAN | 97% | 800 | 1000 |
| Calcitonin, rat | CGNLSTCMLGTYTQDLNKFHTFPQTSIGVGAP-NH2 (C1&C7 bridge) | 97% | 2200 | 2500 |
| Calcitonin, human | CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-NH2 (C1&C7 bridge) | 97% | 2200 | 2500 |
| Human CMV pp65 (495-503) | NLVPMVATV | 97% | 500 | 700 |
| a-Helical Corticotropin Releasing Factor (12-41) | FHLLREMLEMAKAEQEAEQAALNRLLLEEA-NH2 | 97% | 1800 | 2000 |
| Cortistatin 29 (1-13) | Glp-ERPPLQQPPHRD | 97% | 800 | 1000 |
| Proinsulin C-Peptide (55-89), ?human | RREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKR | 97% | 2200 | 2500 |
| SMCY (950-960) (human) | SPSVDKARAEL | 97% | 500 | 700 |
| Delta-Sleep Inducing Peptide | WAGGDASGE | 97% | 500 | 700 |
| Dynorphin A (2-17), porcine | GGFLRRIRPKLKWDNQ | 97% | 800 | 1000 |
| Dynorphin (2-17), amide, porcine | GGFLRRIRPKLKWDNQ-NH2 | 97% | 800 | 1000 |
| Dynorphin B (1-9) | YGGFLRRQF | 97% | 500 | 700 |
| Dynorphin A (1-13), porcine | YGGFLRRIRPKLK | 97% | 800 | 1000 |
| Dynorphin A (1-13), amide, porcine | YGGFLRRIRPKLK-NH2 | 97% | 800 | 1000 |
| Dynorphin A (1-17) | YGGFLRRIRPKLKWDNQ | 97% | 800 | 1000 |
| Dynorphin A amide, porcine | YGGFLRRIRPKLKWDNQ-NH2 | 97% | 800 | 1000 |
| IRL-1720 | Ac-DKEAVYFAHLDIIW | 97% | 800 | 1000 |
| Met-Enkephalin | YGGFM | 97% | 500 | 700 |
| EXENDIN (9-39) | DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 | 97% | 1800 | 2000 |
| Exendin-4 | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 | 97% | 1800 | 2000 |
| Fibronectin CS1 Peptide | EILDVPST | 97% | 500 | 700 |
| G-R-G-D-S-P | GRGDSP | 97% | 500 | 700 |
| Collagen Binding Fragment | CQDSETRTFY | 97% | 500 | 700 |
| [Glu1] Fibrinopeptide B, human | EGVNDNEEGFFSAR | 97% | 500 | 700 |
| [Tyr0] Fibrinopeptide A, human | YADSGEGDFLAEGGGVR | 97% | 800 | 1000 |
| FMRF-amide | FMRF-NH2 | 97% | 500 | 700 |
| Galantide | GWTLNSAGYLLGPQQFFGLM-NH2 | 97% | 850 | 1000 |
| Galanin, rat | GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-NH2 | 97% | 1300 | 1600 |
| Galanin, human | GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS | 97% | 1300 | 1600 |
| M40 | GWTLNSAGYLLGPPPALALA-NH2 | 97% | 900 | 1200 |
| M35 | GWTLNSAGYLLGPPPGFSPFR-NH2 | 97% | 900 | 1200 |
| GHRF (1-29), amide, rat | HADAIFTSSYRRILGQLYARKLLHEIMNR-NH2 | 97% | 1250 | 1600 |
| GHRF (1-29), amide, human | YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2 | 97% | 1250 | 1600 |
| GLP-1 (7-37) (human, bovine, guinea pig, mouse, rat) | HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG | 97% | 1400 | 1700 |
| GLP-1 (7-36), amide, chicken, common turkey | HAEGTYTSDITSYLEGQAAKEFIAWLVNGR-NH2 | 97% | 1400 | 1700 |
| GLP-1/Glucagon-Like Peptide, human | HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG | 97% | 1600 | 2000 |
| GLP-1/Glucagon-Like Peptide, amide, human | HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2 | 97% | 1600 | 2000 |
| [Des-His1,Glu9] Glucagon, amide | SQGTFTSEYSKYLDSRRAQDFVQWLMNT-NH2 | 97% | 1200 | 1500 |
| GLP-2, human | HADGSFSDEMNTILDNLAARDFINWLIQTKITD | 97% | 1600 | 2000 |
| Glucagon-Like Peptide II, human | HADGSFSDEMNTILDNLAARDFINWLIQTKITDR | 97% | 1600 | 2000 |
| Glucagon-Like Peptide II, rat | HADGSFSDEMNTILDNLATRDFINWLIQTKITD | 97% | 1600 | 2000 |
| Glucagon, human | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT | 97% | 1250 | 1600 |
| Epidermal Growth Factor Receptor Peptide (985-996) | DVVDADEYLIPQ | 97% | 500 | 700 |
| Brain Derived Acidic Fibroblast Growth Factor (1-11) | FNLPLGNYKKP | 97% | 500 | 700 |
| Brain Derived Basic Fibroblast Growth Factor (1-24) | PALPEDGGSGAFPPGHFKDPKRLY | 97% | 1050 | 1300 |
| Brain Derived Acidic Fibroblast Growth Factor (102-111) | HAEKHWFVGL | 97% | 500 | 700 |
| GTP-Binding Protein Fragment, Gs alpha | CKQLQKDKQVYRATHR | 97% | 500 | 700 |
| Histone H1-derived Peptide | GGGPATPKKAKKL | 97% | 500 | 700 |
| HIV-1 tat Protein (1-9) | MDPVDPNIE | 97% | 500 | 700 |
| HIV-1 gag Protein p24 (194-210) | ANPDCKTILKALGPAAT | 97% | 750 | 1000 |
| HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) | AVGIGALFLGFLGAAGSTMGARS-NH2 | 97% | 1000 | 1200 |
| HIV (gp41) Fragment | AVGIGA | 97% | 500 | 700 |
| HIV (gp120) Fragment (318-327) | RGPGRAFVTI | 97% | 500 | 700 |
| HIV-1 tat Protein (49-57) | RKKRRQRRR | 97% | 500 | 700 |
| Laminin (925-933) | CDPGYIGSR | 97% | 500 | 700 |
| Laminin A Chain (2091-2108) | CSRARKQAASIKVAVSADR | 97% | 800 | 1000 |
| Laminin (929-933) | YIGSR | 97% | 500 | 700 |
| Laminin Penta Peptide, amide | YIGSR-NH2 | 97% | 500 | 700 |
| Leptin (93-105), human | NVIQISNDLENLR | 97% | 500 | 700 |
| Leptin (116-130), mouse | SCSLPQTSGLQKPES | 97% | 650 | 850 |
| Leucokinin I | DPAFNSWG | 97% | 500 | 700 |
| [DTrp6]-LH-RH, amide | Glp-HWSY-DTrp-LRPG-NH2 | 97% | 500 | 700 |
| LH-RH, Free Acid | Glp-HWSYGLRPG | 97% | 500 | 700 |
| LH-RH, human, Gonadoreline | Glp-HWSYGLRPG-NH2 | 97% | 500 | 700 |
| LH-RH, salmon | Glp-HWSYGWLPG-NH2 | 97% | 500 | 700 |
| LH-RH, lamprey | Glp-HYSLEWKPG-NH2 | 97% | 500 | 700 |
| Mast Cell Degranulating Peptide HR-1 | INLKAIAALVKKVL-NH2 | 97% | 600 | 800 |
| Mast Cell Degranulating Peptide HR-2 | FLPLILGKLVKGLL-NH2 | 97% | 600 | 800 |
| Melanocyte-Stimulating Hormone-Release Inhibiting Factor | PLG-NH2 | 97% | 500 | 700 |
| MAGE-3 Antigen (167-176), human | MEVDPIGHLY | 97% | 500 | 700 |
| MAGE-3 Antigen (271-279), human | FLWGPRALV | 97% | 500 | 700 |
| Mage-1 Antigen (161-169), human | EADPTGHSY | 97% | 500 | 700 |
| (Met 210) Melanoctye Protein PMEL 17 (209-217) (human) | IMDQVPFSV | 97% | 500 | 700 |
| Ile-Thr-Asp-Gln-Val-Pro-Phe-Ser-Val | ITDQVPFSV | 97% | 500 | 700 |
| Trp-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp | WNRQLYPEWTEAQRLD | 97% | 700 | 900 |
| Systemin | AVQSKPPSKRDPPKMQTD | 97% | 700 | 900 |
| Flag Peptide | DYKDDDDK | 97% | 500 | 700 |
| OVA 323-339 | ISQAVHAAHAEINEAGR | 97% | 700 | 900 |
| OVA peptide (257-264) | SIINFEKL | 97% | 500 | 700 |
| Myelin Basic Protein (68-84), guinea pig | YGSLPQKSQRSQDEN | 97% | 700 | 900 |
| Hexa His | HHHHHH | 97% | 500 | 700 |
| Motilin, canine | FVPIFTHSELQKIREKERNKGQ | 97% | 950 | 1150 |
| Motilin, human, porcine | FVPIFTYGELQRMQEKERNKGQ | 97% | 950 | 1150 |
| Myelin Basic Protein (87-99) (human, bovine, rat) | VHFFKNIVTPRTP | 97% | 500 | 700 |
| Neurokinin B | DMHDFFVGLM-NH2 | 97% | 500 | 700 |
| Neurokinin A / Substance K | HKTDSFVGLM-NH2 | 97% | 500 | 700 |
| Neuromedin C | GNHWAVGHLM-NH2 | 97% | 500 | 700 |
| Neuromedin B | GNLWATGHFM-NH2 | 97% | 500 | 700 |
| Neuromedin N | KIPYIL | 97% | 500 | 700 |
| Neuromedin (U25), human | FRVDEEFQSPFASQSRGYFLFRPRN-NH2 | 97% | 1100 | 1300 |
| Neuropeptide Y, human | YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 | 97% | 1600 | 1800 |
| Neuropeptide Y (13-36), human | PAEDMARYYSALRHYINLITRQRY-NH2 | 97% | 1100 | 1300 |
| Neuropeptide K, porcine | DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM-NH2 | 97% | 1600 | 1800 |
| Kassinin | DVPKSDQFVGLM-NH2 | 97% | 700 | 900 |
| Nocistatin | EQKQLQ | 97% | 500 | 700 |
| Mastoparan | INLKALAALAKKIL-NH2 | 97% | 700 | 900 |
| Mastoparan X | INWKGIAAMAKKLL-NH2 | 97% | 700 | 900 |
| Neuropeptide FF | FLFQPQRF-NH2 | 97% | 500 | 700 |
| Diazepam-Binding Inhibitor Fragment, human | QATVGDINTERPGMLDFTGK | 97% | 850 | 1100 |
| Men 10376 | DY-DTrp-V-DTrp-DTrp-K-NH2 | 97% | 500 | 700 |
| Physalaemin | Glp-ADPNKFYGLM-NH2 | 97% | 500 | 700 |
| Phyllomedusin | Glp-NPNRFIGLM-NH2 | 97% | 500 | 700 |
| Corazonin | Glp-TFQYSRGWTN-NH2 | 97% | 500 | 700 |
| Neurotensin (8-13) | RRPYIL | 97% | 500 | 700 |
| Obestatin (human) | FNAPFDVGIKLSGVQYQQHSQAL-NH2 | 97% | 1000 | 1300 |
| Nociceptin / Orphanin FQ | FGGFTGARKSARKLANQ | 97% | 750 | 1000 |
| Orexin B, canine | RPGPPGLQGRLQRLLQASGNHAAGILTM-NH2 | 97% | 1200 | 1500 |
| Orexin B, human | RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2 | 97% | 1200 | 1500 |
| PACAP (1-38), human, ovine, rat | HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 | 97% | 1700 | 2000 |
| PACAP-Related Peptide (PRP), rat | DVAHEILNEAYRKVLDQLSARKYLQSMVA | 97% | 1200 | 1500 |
| PACAP-Related Peptide (PRP), human | DVAHGILNEAYRKVLDQLSAGKHLQSLVA | 97% | 1200 | 1500 |
| PACAP (1-27), human, ovine, rat | HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2 | 97% | 1200 | 1500 |
| PACAP (6-27), human, ovine, rat | FTDSYSRYRKQMAVKKYLAAVL-NH2 | 97% | 1200 | 1500 |
| Chromostatin, bovine | SDEDSDGDRPQASPGLGPGP | 97% | 1200 | 1500 |
| Pancreatic Polypeptide (rat) | APLEPMYPGDYATHEQRAQYETQLRRYINTLTRPRY-NH2 | 97% | 1700 | 2000 |
| Pancreatic Polypeptide (human) | APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 | 97% | 1700 | 2000 |
| Insulin B (9 - 23) | SHLVEALYLVCGERG | 97% | 650 | 900 |
| PAR - 1 Agonist;Protease - Activated Receptor - 1 | TFLLRN | 97% | 500 | 700 |
| PAR-4 (1-6) amide (human) | GYPGQV-NH2 | 97% | 500 | 700 |
| PAR-4 (1-6) (human) | GYPGQV | 97% | 500 | 700 |
| PAR-4 (1-6) amide (mouse) | GYPGKF-NH2 | 97% | 500 | 700 |
| PAR-4 (1-6) (mouse) | GYPGKF | 97% | 500 | 700 |
| P34cdc2 Kinase Substrate Peptide | ADAQHATPPKKKRKVEDPKDF | 97% | 750 | 1000 |
| Tyrosinase (206-214), human | AFLPWHRLF | 97% | 650 | 900 |
| Substrate for Tyrosine Protein Kinase | RRLIEDNEYTARG | 97% | 650 | 900 |
| S6-1 | RRLSSLRA | 97% | 650 | 900 |
| Phosphate Acceptor Peptide | RRKASGPPV | 97% | 650 | 900 |
| Malantide | RTKRSGSVYEPLKI | 97% | 650 | 900 |
| Protease-Activated Receptor-2, PAR-2 Agonist, amide | SLIGKV-NH2 | 97% | 650 | 900 |
| Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 | 97% | 1200 | 1500 |
| Kemptide | LRRASLG | 97% | 650 | 900 |
| Phosphorylase Kinase b-Subunit (420-436) | KRNPGSQKRFPSNCGRD | 97% | 750 | 1000 |
| Myosin Kinase Inhibiting Peptide | KKRAARATS-NH2 | 97% | 650 | 900 |
| Syntide 2 | PLARTLSVAGLPGKK | 97% | 650 | 900 |
| Tyrosinase (192-200), human mouse | SEIWRDIDF | 97% | 650 | 900 |
| Tyr-Ile-Tyr-Gly-Ser-Phe-Lys | YIYGSFK | 97% | 500 | 700 |
| Casein Kinase II Substrate | RRREEETEEE | 97% | 650 | 900 |
| Ser25] Protein Kinase C (19-31) | RFARKGSLRQKNV | 97% | 650 | 900 |
| [Ala9] Autocamtide 2 | KKALRRQEAVDAL | 97% | 650 | 900 |
| Autocamtide 2 | KKALRRQETVDAL | 97% | 650 | 900 |
| cAMP Dependent PK Inhibitor (5-22), amide | TTYADFIASGRTGRRNAI-NH2 | 97% | 800 | 1000 |
| RR-SRC | RRLIEDAEYAARG | 97% | 650 | 900 |
| Protein Kinase C (19-35) Peptide | RFARKGALRQKNVHEVK | 97% | 800 | 1000 |
| Protein Kinase C (gamma) Peptide | NYPLELYERVRTGC | 97% | 650 | 900 |
| Hypercalcemia Malignancy Factor (1-34), human | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA | 97% | 1500 | 1800 |
| Hypercalcemia Malignancy Factor (1-34), amide, human | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA-NH2 | 97% | 1500 | 1800 |
| Parathyroid Hormone (1-34), rat | AVSEIQLMHNLGKHLASVERMQWLRKKLQDVHNF | 97% | 1500 | 1800 |
| Parathyroid Hormone (1-34), bovine | AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNF | 97% | 1500 | 1800 |
| Angiotensinogen (1-14), human | DRVYIHPFHLVIHN | 97% | 650 | 900 |
| Acetyl Angiotensinogen (1-14), porcine | Ac-DRVYIHPFHLLVYS | 97% | 650 | 900 |
| Acetyl, Angiotensinogen (1-14), human | Ac-DRVYIHPFHLVIHN | 97% | 650 | 900 |
| Renin Substrate Tetradecapeptide, rat | DRVYIHPFHLLYYS | 97% | 650 | 900 |
| Angiotensinogen (1-14), porcine | DRVYIHPFHLLVYS | 97% | 650 | 900 |
| Angiotensinogen (1-13), human | DRVYIHPFHLVIH | 97% | 650 | 900 |
| P-H-P-F-H-F-F-V-Y-K | PHPFHFFVYK | 97% | 650 | 900 |
| [Cys8] Renin Substrate Tetradecapeptide, rat | DRVYIHPCHLLYYS | 97% | 650 | 900 |
| [Leu8] Renin Substrate Tetradecapeptide, rat | DRVYIHPLHLLYYS | 97% | 650 | 900 |
| [Val8] Renin Substrate Tetradecapeptide, rat | DRVYIHPVHLLYYS | 97% | 650 | 900 |
| Secretin, rat | HSDGTFTSELSRLQDSARLQRLLQGLV-NH2 | 97% | 1200 | 1400 |
| Secretin (5-27), porcine | TFTSELSRLRDSARLQRLLQGLV-NH2 | 97% | 1200 | 1400 |
| Secretin, human | HSDGTFTSELSRLREGARLQRLLQGLV-NH2 | 97% | 1200 | 1400 |
| Selank | TKPRPGP | 97% | 500 | 700 |
| Somatostatin 28 (1-14) | SANSNPAMAPRERK | 97% | 500 | 700 |
| Somatostatin1-14 | AGCKNFFWKTFTSC (C3&C14 bridge) | 97% | 1100 | 1400 |
| RC-160 (Vapreotide) | fCYwKVCW-NH2 (C2&C7 bridge) | 97% | 1100 | 1400 |
| NTB (Naltriben) | DPhe-CY-DTrp-Orn-T-Pen-T-NH2(Cys2&Pen7 bridge) | 97% | 1100 | 1400 |
| [DPro2,DPhe7,DTrp9] Substance P | R-DPro-KPQQ-DPhe-F-DTrp-LM-NH2 | 97% | 650 | 900 |
| MG-132 | RPKPQQFFGLM-NH2 | 97% | 650 | 900 |
| Pep-1 | KETWWETWWTEWSQPKKKRKV | 97% | 900 | 1100 |
| TAT 2-4 | YGRKKRRQRRRGYGRKKRRQRRRG | 97% | 900 | 1200 |
| Scrambled TRAP Fragment | FSLLRN-NH2 | 97% | 500 | 700 |
| Hemoglobin (Hb) (64-76) | GKKVITAFNEGLK | 97% | 500 | 700 |
| Thymopoietin II (32-34) | RKD | 97% | 500 | 700 |
| Thymopoietin II (32-35) | RKDV | 97% | 500 | 700 |
| Thymopentin | RKDVY | 97% | 500 | 700 |
| Urocortin II, human | IVLSLDVPIGLLQILLEQARARAAREQATTNARILARVGHC-NH2 | 97% | 1900 | 2200 |
| Urocortin III, mouse | FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI-NH2 | 97% | 1900 | 2200 |
| Urocortin III, human | FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI-NH2 | 97% | 1900 | 2200 |
| Urocortin, human | DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 | 97% | 1900 | 2200 |
| Urocortin, rat | DDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 | 97% | 1900 | 2200 |
| Urocortin III, mouse, free acid | FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI | 97% | 1900 | 2200 |
| Urotensin I | NDDPPISIDLTFHLLRNMIEMARIENEREQAGLNRKYLDEV-NH2 | 97% | 1900 | 2200 |
| VIP, human, porcine, rat, ovine | HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2 | 97% | 1200 | 1400 |
| PHI, rat | HADGVFTSDYSRLLGQISAKKYLESLI-NH2 | 97% | 1200 | 1400 |
| VIP, guinea pig | HSDALFTDTYTRLRKQMAMKKYLNSVLN-NH2 | 97% | 1200 | 1400 |
| Peptide T | ASTTTNYT | 97% | 500 | 700 |
| R15K, HIV-1 Inhibitory Peptide | RIQRGPGRAFVTIGK | 97% | 650 | 900 |
95纯度的参考价：
| Name | Sequence | Quantity | Weight | Price |
| Angiotensin I Converting Enzyme Inhibitor | RPGFSPFR | ≥95.0% | 1mg | ￥120 |
| Angiotensin I Converting Enzyme Inhibitor | RPGFSPFR | ≥95.0% | 5mg | ￥360 |
| Angiotensin Converting Enzyme Inhibitor | Glp-WPRPQIPP | ≥95.0% | 1mg | ￥135 |
| Angiotensin Converting Enzyme Inhibitor | Glp-WPRPQIPP | ≥95.0% | 5mg | ￥405 |
| Acetalin-3 | Ac-RFMWMK-NH2 | ≥95.0% | 1mg | ￥110 |
| Acetalin-3 | Ac-RFMWMK-NH2 | ≥95.0% | 5mg | ￥330 |
| Acetalin-2 | Ac-RFMWMR-NH2 | ≥95.0% | 1mg | ￥110 |
| Acetalin-2 | Ac-RFMWMR-NH2 | ≥95.0% | 5mg | ￥330 |
| Acetalin-1 | Ac-RFMWMT-NH2 | ≥95.0% | 1mg | ￥110 |
| Acetalin-1 | Ac-RFMWMT-NH2 | ≥95.0% | 5mg | ￥330 |
| ACTH (18-39), human | RPVKVYPNGAEDESAEAFPLEF | ≥95.0% | 1mg | ￥330 |
| ACTH (18-39), human | RPVKVYPNGAEDESAEAFPLEF | ≥95.0% | 5mg | ￥990 |
| ACTH (6-24), human | HFRWGKPVGKKRRPVKVYP | ≥95.0% | 1mg | ￥285 |
| ACTH (6-24), human | HFRWGKPVGKKRRPVKVYP | ≥95.0% | 5mg | ￥285 |
| ACTH (4-10), human | MEHFRWG | ≥95.0% | 1mg | ￥105 |
| ACTH (4-10), human | MEHFRWG | ≥95.0% | 5mg | ￥315 |
| ACTH (4-11), human | MEHFRWGK | ≥95.0% | 1mg | ￥120 |
| ACTH (4-11), human | MEHFRWGK | ≥95.0% | 5mg | ￥360 |
| ACTH (1-10), human | SYSMEHFRWG | ≥95.0% | 1mg | ￥150 |
| ACTH (1-10), human | SYSMEHFRWG | ≥95.0% | 5mg | ￥450 |
| ACTH (1-13), human | SYSMEHFRWGKPV | ≥95.0% | 1mg | ￥165 |
| ACTH (1-13), human | SYSMEHFRWGKPV | ≥95.0% | 5mg | ￥495 |
| ACTH (1-16), human | SYSMEHFRWGKPVGKK | ≥95.0% | 1mg | ￥240 |
| ACTH (1-16), human | SYSMEHFRWGKPVGKK | ≥95.0% | 5mg | ￥720 |
| ACTH (1-17), human | SYSMEHFRWGKPVGKKR | ≥95.0% | 1mg | ￥255 |
| ACTH (1-17), human | SYSMEHFRWGKPVGKKR | ≥95.0% | 5mg | ￥765 |
| ACTH (1-24), human | SYSMEHFRWGKPVGKKRRPVKVYP | ≥95.0% | 1mg | ￥360 |
| ACTH (1-24), human | SYSMEHFRWGKPVGKKRRPVKVYP | ≥95.0% | 5mg | ￥1,080 |
| ACTH (1-39), human | SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF | ≥95.0% | 1mg | ￥624 |
| ACTH (1-39), human | SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF | ≥95.0% | 5mg | ￥1,872 |
| ACTH (1-39), rat | SYSMEHFRWGKPVGKKRRPVKVYPNVAENESAEAFPLEF | ≥95.0% | 1mg | ￥624 |
| ACTH (1-39), rat | SYSMEHFRWGKPVGKKRRPVKVYPNVAENESAEAFPLEF | ≥95.0% | 5mg | ￥1,872 |
| N-Acetyl, ACTH (1-17), human | Ac-SYSMEHFRWGKPVGKKR | ≥95.0% | 1mg | ￥255 |
| N-Acetyl, ACTH (1-17), human | Ac-SYSMEHFRWGKPVGKKR | ≥95.0% | 5mg | ￥765 |
| Pro-Adrenomedullin (N-20), rat | ARLDTSSQFRKKWNKWALSR-NH2 | ≥95.0% | 1mg | ￥312 |
| Pro-Adrenomedullin (N-20), rat | ARLDTSSQFRKKWNKWALSR-NH2 | ≥95.0% | 5mg | ￥936 |
| Pro-Adrenomedullin (N-20), porcine | ARLDVAAEFRKKWNKWALSR-NH2 | ≥95.0% | 1mg | ￥312 |
| Pro-Adrenomedullin (N-20), porcine | ARLDVAAEFRKKWNKWALSR-NH2 | ≥95.0% | 5mg | ￥936 |
| Pro-Adrenomedullin (N-20), human | ARLDVASEFRKKWNKWALSR-NH2 | ≥95.0% | 1mg | ￥312 |
| Pro-Adrenomedullin (N-20), human | ARLDVASEFRKKWNKWALSR-NH2 | ≥95.0% | 5mg | ￥936 |
| Adrenomedullin (22-52), human | TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH2 | ≥95.0% | 1mg | ￥527 |
| Adrenomedullin (22-52), human | TVQKLAHQIYQFTDKDKDNVAPRSKISPQGY-NH2 | ≥95.0% | 5mg | ￥1,581 |
| Adrenomedullin (1-12), human | YRQSMNNFQGLR | ≥95.0% | 1mg | ￥120 |
| Adrenomedullin (1-12), human | YRQSMNNFQGLR | ≥95.0% | 5mg | ￥360 |
| Allatostatins/Allatostatin I | APSGAQRLYGFGL-NH2 | ≥95.0% | 1mg | ￥205 |
| Allatostatins/Allatostatin I | APSGAQRLYGFGL-NH2 | ≥95.0% | 5mg | ￥615 |
| Allatostatin IV | DRLYSFGL-NH2 | ≥95.0% | 1mg | ￥130 |
| Allatostatin IV | DRLYSFGL-NH2 | ≥95.0% | 5mg | ￥390 |
| Allatostatin II | GDGRLYAFGL-NH2 | ≥95.0% | 1mg | ￥160 |
| Allatostatin II | GDGRLYAFGL-NH2 | ≥95.0% | 5mg | ￥480 |
| Allatostatin III | GGSLYSFGL-NH2 | ≥95.0% | 1mg | ￥145 |
| Allatostatin III | GGSLYSFGL-NH2 | ≥95.0% | 5mg | ￥435 |
| Magainin Spacer Peptide | DAEAVGPEAFADQDLDEREVR | ≥95.0% | 1mg | ￥316 |
| Magainin Spacer Peptide | DAEAVGPEAFADQDLDEREVR | ≥95.0% | 5mg | ￥948 |
| Histatin 5 | DSHAKRHHGYKRKFHEKHHSHRGY | ≥95.0% | 1mg | ￥360 |
| Histatin 5 | DSHAKRHHGYKRKFHEKHHSHRGY | ≥95.0% | 5mg | ￥1,080 |
| Indolicidin | ILPWKWPWWPWRR-NH2 | ≥95.0% | 1mg | ￥205 |
| Indolicidin | ILPWKWPWWPWRR-NH2 | ≥95.0% | 5mg | ￥615 |
| Angiotensin III, human | RVYIHPF | ≥95.0% | 1mg | ￥105 |
| Angiotensin III, human | RVYIHPF | ≥95.0% | 5mg | ￥315 |
| Angiotensin II, human | DRVYIHPF | ≥95.0% | 1mg | ￥120 |
| Angiotensin II, human | DRVYIHPF | ≥95.0% | 5mg | ￥360 |
| Angiotensin I, human | DRVYIHPFHL | ≥95.0% | 1mg | ￥150 |
| Angiotensin I, human | DRVYIHPFHL | ≥95.0% | 5mg | ￥450 |
| CD36 Peptide P (139-155) | CNLAVAAASHIYQNQFVQ | ≥95.0% | 1mg | ￥255 |
| CD36 Peptide P (139-155) | CNLAVAAASHIYQNQFVQ | ≥95.0% | 5mg | ￥765 |
| Angiotensin II Antipeptide | EGVYVHPV | ≥95.0% | 1mg | ￥120 |
| Angiotensin II Antipeptide | EGVYVHPV | ≥95.0% | 5mg | ￥360 |
| Angiotensin II (5-8), human | IHPF | ≥95.0% | 1mg | ￥60 |
| Angiotensin II (5-8), human | IHPF | ≥95.0% | 5mg | ￥180 |
| CD36 Peptide P (93-110) | YRVRFLAKENVTQDAEDNC | ≥95.0% | 1mg | ￥270 |
| CD36 Peptide P (93-110) | YRVRFLAKENVTQDAEDNC | ≥95.0% | 5mg | ￥810 |
| Biotinyl-Angiotensin I | Biotin-DRVYIHPFHL | ≥95.0% | 1mg | ￥175 |
| Biotinyl-Angiotensin I | Biotin-DRVYIHPFHL | ≥95.0% | 5mg | ￥525 |
| Fibrinogen-Binding Peptide | EHIPA | ≥95.0% | 1mg | ￥75 |
| Fibrinogen-Binding Peptide | EHIPA | ≥95.0% | 5mg | ￥225 |
| Anti-Inflammatory Peptide 1 | MQMKKVLDS | ≥95.0% | 1mg | ￥135 |
| Anti-Inflammatory Peptide 1 | MQMKKVLDS | ≥95.0% | 5mg | ￥405 |
| Cecropin P1, porcine | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | ≥95.0% | 1mg | ￥480 |
| Cecropin P1, porcine | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | ≥95.0% | 5mg | ￥1,440 |
| Cecropin A-melittin hybrid peptide [CA(1-7)M(2-9)NH2] | KWKLFKKIGAVLKVL-NH2 | ≥95.0% | 1mg | ￥235 |
| Cecropin A-melittin hybrid peptide [CA(1-7)M(2-9)NH2] | KWKLFKKIGAVLKVL-NH2 | ≥95.0% | 5mg | ￥705 |
| Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | ≥95.0% | 1mg | ￥368 |
| Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | ≥95.0% | 5mg | ￥1,104 |
| Magainin I | GIGKFLHSAGKFGKAFVGEIMKS | ≥95.0% | 1mg | ￥368 |
| Magainin I | GIGKFLHSAGKFGKAFVGEIMKS | ≥95.0% | 5mg | ￥1,104 |
| Lactoferricin, bovine, (BLFC) | RRWQWRMKKLG | ≥95.0% | 1mg | ￥165 |
| Lactoferricin, bovine, (BLFC) | RRWQWRMKKLG | ≥95.0% | 5mg | ￥495 |
| Apelin-13, human, bovine | QRPRLSHKGPMPF | ≥95.0% | 1mg | ￥195 |
| Apelin-13, human, bovine | QRPRLSHKGPMPF | ≥95.0% | 5mg | ￥585 |
| (Glp1)-Apelin-13, human, bovine | Glp-RPRLSHKGPMPF | ≥95.0% | 1mg | ￥220 |
| (Glp1)-Apelin-13, human, bovine | Glp-RPRLSHKGPMPF | ≥95.0% | 5mg | ￥660 |
| α-Bag Cell Peptide (1-7) | APRLRFY | ≥95.0% | 1mg | ￥105 |
| α-Bag Cell Peptide (1-7) | APRLRFY | ≥95.0% | 5mg | ￥315 |
| α-Bag Cell Peptide (1-8) | APRLRFYS | ≥95.0% | 1mg | ￥120 |
| α-Bag Cell Peptide (1-8) | APRLRFYS | ≥95.0% | 5mg | ￥360 |
| α-Bag Cell Peptide (1-9) | APRLRFYSL | ≥95.0% | 1mg | ￥135 |
| α-Bag Cell Peptide (1-9) | APRLRFYSL | ≥95.0% | 5mg | ￥405 |
| γ-Bag Cell Factor | RLRFD | ≥95.0% | 1mg | ￥75 |
| γ-Bag Cell Factor | RLRFD | ≥95.0% | 5mg | ￥225 |
| β-Bag Cell Factor | RLRFH | ≥95.0% | 1mg | ￥75 |
| β-Bag Cell Factor | RLRFH | ≥95.0% | 5mg | ￥225 |
| β-Amyloid (1-14) | DAEFRHDSGYEVHH | ≥95.0% | 1mg | ￥280 |
| β-Amyloid (1-14) | DAEFRHDSGYEVHH | ≥95.0% | 5mg | ￥840 |
| β-Amyloid (1-13) | DAEFRHDSGYEVH | ≥95.0% | 1mg | ￥260 |
| β-Amyloid (1-13) | DAEFRHDSGYEVH | ≥95.0% | 5mg | ￥780 |
| β-Amyloid (1-12) | DAEFRHDSGYEV | ≥95.0% | 1mg | ￥240 |
| β-Amyloid (1-12) | DAEFRHDSGYEV | ≥95.0% | 5mg | ￥720 |
| β-Amyloid (1-11) | DAEFRHDSGYE | ≥95.0% | 1mg | ￥220 |
| β-Amyloid (1-11) | DAEFRHDSGYE | ≥95.0% | 5mg | ￥660 |
| β-Amyloid (1-10) | DAEFRHDSGY | ≥95.0% | 1mg | ￥200 |
| β-Amyloid (1-10) | DAEFRHDSGY | ≥95.0% | 5mg | ￥600 |
| β-Amyloid (1-9) | DAEFRHDSG | ≥95.0% | 1mg | ￥180 |
| β-Amyloid (1-9) | DAEFRHDSG | ≥95.0% | 5mg | ￥540 |
| β-Amyloid (1-20) | DAEFRHDSGYEVHHQKLVFF | ≥95.0% | 1mg | ￥400 |
| β-Amyloid (1-20) | DAEFRHDSGYEVHHQKLVFF | ≥95.0% | 5mg | ￥1,200 |
| β-Amyloid (1-18) | DAEFRHDSGYEVHHQKLV | ≥95.0% | 1mg | ￥360 |
| β-Amyloid (1-18) | DAEFRHDSGYEVHHQKLV | ≥95.0% | 5mg | ￥1,080 |
| Bombesin | Glp-QRLGNQWAVGHLM-NH2 | ≥95.0% | 1mg | ￥254 |
| Bombesin | Glp-QRLGNQWAVGHLM-NH2 | ≥95.0% | 5mg | ￥762 |
| Osteocalcin (37-49), human | GFQEAYRRFYGPV | ≥95.0% | 1mg | ￥195 |
| Osteocalcin (37-49), human | GFQEAYRRFYGPV | ≥95.0% | 5mg | ￥585 |
| Myelopeptide-2 (MP-2) | LVVYPW | ≥95.0% | 1mg | ￥90 |
| Myelopeptide-2 (MP-2) | LVVYPW | ≥95.0% | 5mg | ￥270 |
| Bone Gla Protein (45-49) | FYGPV | ≥95.0% | 1mg | ￥75 |
| Bone Gla Protein (45-49) | FYGPV | ≥95.0% | 5mg | ￥225 |
| [Tyr38, Phe42,46] Bone Gla Protein | YQEAFRRFFGPV | ≥95.0% | 1mg | ￥180 |
| [Tyr38, Phe42,46] Bone Gla Protein | YQEAFRRFFGPV | ≥95.0% | 5mg | ￥540 |
| [Tyr0] Bradykinin | YRPPGFSPFR | ≥95.0% | 1mg | ￥150 |
| [Tyr0] Bradykinin | YRPPGFSPFR | ≥95.0% | 5mg | ￥450 |
| Bradykinin | RPPGFSPFR | ≥95.0% | 1mg | ￥135 |
| Bradykinin | RPPGFSPFR | ≥95.0% | 5mg | ￥405 |
| [Thi5,8,DPhe7] Bradykinin | RPPG-Thi-S-DPhe-Thi-R | ≥95.0% | 1mg | ￥210 |
| [Thi5,8,DPhe7] Bradykinin | RPPG-Thi-S-DPhe-Thi-R | ≥95.0% | 5mg | ￥630 |
| Fam-Bradykinin | 5FAM-RPPGFSPFR | ≥95.0% | 1mg | ￥235 |
| Fam-Bradykinin | 5FAM-RPPGFSPFR | ≥95.0% | 5mg | ￥705 |
| CART (55-76), rat | IPIYEKKYGQVPMCDAGEQCAV(Cys14&Cys20 bridge) | ≥95.0% | 1mg | ￥352 |
| CART (55-76), rat | IPIYEKKYGQVPMCDAGEQCAV(Cys14&Cys20 bridge) | ≥95.0% | 5mg | ￥1,056 |
| Cholecystokinin, CCK Tetrapeptide (30-33) | WMDF-NH2 | ≥95.0% | 1mg | ￥70 |
| Cholecystokinin, CCK Tetrapeptide (30-33) | WMDF-NH2 | ≥95.0% | 5mg | ￥210 |
| Cholecystokinin, CCK Octapeptide (26-33), Non-Sulfated form | DYMGWMDF-NH2 | ≥95.0% | 1mg | ￥130 |
| Cholecystokinin, CCK Octapeptide (26-33), Non-Sulfated form | DYMGWMDF-NH2 | ≥95.0% | 5mg | ￥390 |
| Katacalcin | DMSSDLERDHRPHVSMPQNAN | ≥95.0% | 1mg | ￥315 |
| Katacalcin | DMSSDLERDHRPHVSMPQNAN | ≥95.0% | 5mg | ￥945 |
| Calcitonin, rat | CGNLSTCMLGTYTQDLNKFHTFPQTSIGVGAP-NH2 (C1&C7 bridge) | ≥95.0% | 1mg | ￥664 |
| Calcitonin, rat | CGNLSTCMLGTYTQDLNKFHTFPQTSIGVGAP-NH2 (C1&C7 bridge) | ≥95.0% | 5mg | ￥1,992 |
| Calcitonin, human | CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-NH2 (C1&C7 bridge) | ≥95.0% | 1mg | ￥664 |
| Calcitonin, human | CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-NH2 (C1&C7 bridge) | ≥95.0% | 5mg | ￥1,992 |
| Human CMV pp65 (495-503) | NLVPMVATV | ≥95.0% | 1mg | ￥135 |
| Human CMV pp65 (495-503) | NLVPMVATV | ≥95.0% | 5mg | ￥405 |
| a-Helical Corticotropin Releasing Factor (12-41) | FHLLREMLEMAKAEQEAEQAALNRLLLEEA-NH2 | ≥95.0% | 1mg | ￥492 |
| a-Helical Corticotropin Releasing Factor (12-41) | FHLLREMLEMAKAEQEAEQAALNRLLLEEA-NH2 | ≥95.0% | 5mg | ￥1,476 |
| Cortistatin 29 (1-13) | Glp-ERPPLQQPPHRD | ≥95.0% | 1mg | ￥195 |
| Cortistatin 29 (1-13) | Glp-ERPPLQQPPHRD | ≥95.0% | 5mg | ￥585 |
| Proinsulin C-Peptide (55-89), ?human | RREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKR | ≥95.0% | 1mg | ￥630 |
| Proinsulin C-Peptide (55-89), ?human | RREAEDLQVGQVELGGGPGAGSLQPLALEGSLQKR | ≥95.0% | 5mg | ￥1,890 |
| SMCY (950-960) (human) | SPSVDKARAEL | ≥95.0% | 1mg | ￥165 |
| SMCY (950-960) (human) | SPSVDKARAEL | ≥95.0% | 5mg | ￥495 |
| Delta-Sleep Inducing Peptide | WAGGDASGE | ≥95.0% | 1mg | ￥135 |
| Delta-Sleep Inducing Peptide | WAGGDASGE | ≥95.0% | 5mg | ￥405 |
| DISP | WAGGDASGE | ≥98.0% | 1mg | ￥162 |
| DISP | WAGGDASGE | ≥98.0% | 5mg | ￥486 |
| Dynorphin A (2-17), porcine | GGFLRRIRPKLKWDNQ | ≥95.0% | 1mg | ￥240 |
| Dynorphin A (2-17), porcine | GGFLRRIRPKLKWDNQ | ≥95.0% | 5mg | ￥720 |
| Dynorphin (2-17), amide, porcine | GGFLRRIRPKLKWDNQ-NH2 | ≥95.0% | 1mg | ￥250 |
| Dynorphin (2-17), amide, porcine | GGFLRRIRPKLKWDNQ-NH2 | ≥95.0% | 5mg | ￥750 |
| Dynorphin B (1-9) | YGGFLRRQF | ≥95.0% | 1mg | ￥135 |
| Dynorphin B (1-9) | YGGFLRRQF | ≥95.0% | 5mg | ￥405 |
| Dynorphin A (1-13), porcine | YGGFLRRIRPKLK | ≥95.0% | 1mg | ￥195 |
| Dynorphin A (1-13), porcine | YGGFLRRIRPKLK | ≥95.0% | 5mg | ￥585 |
| Dynorphin A (1-13), amide, porcine | YGGFLRRIRPKLK-NH2 | ≥95.0% | 1mg | ￥205 |
| Dynorphin A (1-13), amide, porcine | YGGFLRRIRPKLK-NH2 | ≥95.0% | 5mg | ￥615 |
| Dynorphin A (1-17) | YGGFLRRIRPKLKWDNQ | ≥95.0% | 1mg | ￥255 |
| Dynorphin A (1-17) | YGGFLRRIRPKLKWDNQ | ≥95.0% | 5mg | ￥765 |
| Dynorphin A amide, porcine | YGGFLRRIRPKLKWDNQ-NH2 | ≥95.0% | 1mg | ￥265 |
| Dynorphin A amide, porcine | YGGFLRRIRPKLKWDNQ-NH2 | ≥95.0% | 5mg | ￥795 |
| IRL-1720 | Ac-DKEAVYFAHLDIIW | ≥95.0% | 1mg | ￥225 |
| IRL-1720 | Ac-DKEAVYFAHLDIIW | ≥95.0% | 5mg | ￥675 |
| Met-Enkephalin | YGGFM | ≥95.0% | 1mg | ￥75 |
| Met-Enkephalin | YGGFM | ≥95.0% | 5mg | ￥225 |
| EXENDIN (9-39) | DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 | ≥95.0% | 1mg | ￥527 |
| EXENDIN (9-39) | DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 | ≥95.0% | 5mg | ￥1,581 |
| Exendin-4 | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 | ≥95.0% | 1mg | ￥720 |
| Exendin-4 | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 | ≥95.0% | 5mg | ￥2,160 |
| Fibronectin CS1 Peptide | EILDVPST | ≥95.0% | 1mg | ￥120 |
| Fibronectin CS1 Peptide | EILDVPST | ≥95.0% | 5mg | ￥360 |
| G-R-G-D-S-P | GRGDSP | ≥95.0% | 1mg | ￥90 |
| G-R-G-D-S-P | GRGDSP | ≥95.0% | 5mg | ￥270 |
| Collagen Binding Fragment | CQDSETRTFY | ≥95.0% | 1mg | ￥150 |
| Collagen Binding Fragment | CQDSETRTFY | ≥95.0% | 5mg | ￥450 |
| [Glu1] Fibrinopeptide B, human | EGVNDNEEGFFSAR | ≥95.0% | 1mg | ￥210 |
| [Glu1] Fibrinopeptide B, human | EGVNDNEEGFFSAR | ≥95.0% | 5mg | ￥630 |
| [Tyr0] Fibrinopeptide A, human | YADSGEGDFLAEGGGVR | ≥95.0% | 1mg | ￥255 |
| [Tyr0] Fibrinopeptide A, human | YADSGEGDFLAEGGGVR | ≥95.0% | 5mg | ￥765 |
| FMRF-amide | FMRF-NH2 | ≥95.0% | 1mg | ￥70 |
| FMRF-amide | FMRF-NH2 | ≥95.0% | 5mg | ￥210 |
| Galantide | GWTLNSAGYLLGPQQFFGLM-NH2 | ≥95.0% | 1mg | ￥330 |
| Galantide | GWTLNSAGYLLGPQQFFGLM-NH2 | ≥95.0% | 5mg | ￥990 |
| Galanin, rat | GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-NH2 | ≥95.0% | 1mg | ￥474 |
| Galanin, rat | GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-NH2 | ≥95.0% | 5mg | ￥1,422 |
| Galanin, human | GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS | ≥95.0% | 1mg | ￥510 |
| Galanin, human | GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS | ≥95.0% | 5mg | ￥1,530 |
| M40 | GWTLNSAGYLLGPPPALALA-NH2 | ≥95.0% | 1mg | ￥310 |
| M40 | GWTLNSAGYLLGPPPALALA-NH2 | ≥95.0% | 5mg | ￥930 |
| M35 | GWTLNSAGYLLGPPPGFSPFR-NH2 | ≥95.0% | 1mg | ￥326 |
| M35 | GWTLNSAGYLLGPPPGFSPFR-NH2 | ≥95.0% | 5mg | ￥978 |
| GHRF (1-29), amide, rat | HADAIFTSSYRRILGQLYARKLLHEIMNR-NH2 | ≥95.0% | 1mg | ￥474 |
| GHRF (1-29), amide, rat | HADAIFTSSYRRILGQLYARKLLHEIMNR-NH2 | ≥95.0% | 5mg | ￥1,422 |
| GHRF (1-29), amide, human | YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2 | ≥95.0% | 1mg | ￥474 |
| GHRF (1-29), amide, human | YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2 | ≥95.0% | 5mg | ￥1,422 |
| GLP-1 (7-37) (human, bovine, guinea pig, mouse, rat) | HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG | ≥95.0% | 1mg | ￥527 |
| GLP-1 (7-37) (human, bovine, guinea pig, mouse, rat) | HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG | ≥95.0% | 5mg | ￥1,581 |
| GLP-1 (7-36), amide, chicken, common turkey | HAEGTYTSDITSYLEGQAAKEFIAWLVNGR-NH2 | ≥95.0% | 1mg | ￥510 |
| GLP-1 (7-36), amide, chicken, common turkey | HAEGTYTSDITSYLEGQAAKEFIAWLVNGR-NH2 | ≥95.0% | 5mg | ￥1,530 |
| GLP-1/Glucagon-Like Peptide, human | HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG | ≥95.0% | 1mg | ￥660 |
| GLP-1/Glucagon-Like Peptide, human | HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG | ≥95.0% | 5mg | ￥1,980 |
| GLP-1/Glucagon-Like Peptide, amide, human | HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2 | ≥95.0% | 1mg | ￥680 |
| GLP-1/Glucagon-Like Peptide, amide, human | HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2 | ≥95.0% | 5mg | ￥2,040 |
| [Des-His1,Glu9] Glucagon, amide | SQGTFTSEYSKYLDSRRAQDFVQWLMNT-NH2 | ≥95.0% | 1mg | ￥680 |
| [Des-His1,Glu9] Glucagon, amide | SQGTFTSEYSKYLDSRRAQDFVQWLMNT-NH2 | ≥95.0% | 5mg | ￥2,040 |
| GLP-2, human | HADGSFSDEMNTILDNLAARDFINWLIQTKITD | ≥95.0% | 1mg | ￥561 |
| GLP-2, human | HADGSFSDEMNTILDNLAARDFINWLIQTKITD | ≥95.0% | 5mg | ￥1,683 |
| Glucagon-Like Peptide II, human | HADGSFSDEMNTILDNLAARDFINWLIQTKITDR | ≥95.0% | 1mg | ￥578 |
| Glucagon-Like Peptide II, human | HADGSFSDEMNTILDNLAARDFINWLIQTKITDR | ≥95.0% | 5mg | ￥1,734 |
| Glucagon-Like Peptide II, rat | HADGSFSDEMNTILDNLATRDFINWLIQTKITD | ≥95.0% | 1mg | ￥561 |
| Glucagon-Like Peptide II, rat | HADGSFSDEMNTILDNLATRDFINWLIQTKITD | ≥95.0% | 5mg | ￥1,683 |
| Glucagon, human | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT | ≥95.0% | 1mg | ￥464 |
| Glucagon, human | HSQGTFTSDYSKYLDSRRAQDFVQWLMNT | ≥95.0% | 5mg | ￥1,392 |
| Epidermal Growth Factor Receptor Peptide (985-996) | DVVDADEYLIPQ | ≥95.0% | 1mg | ￥180 |
| Epidermal Growth Factor Receptor Peptide (985-996) | DVVDADEYLIPQ | ≥95.0% | 5mg | ￥540 |
| Brain Derived Acidic Fibroblast Growth Factor (1-11) | FNLPLGNYKKP | ≥95.0% | 1mg | ￥165 |
| Brain Derived Acidic Fibroblast Growth Factor (1-11) | FNLPLGNYKKP | ≥95.0% | 5mg | ￥495 |
| Brain Derived Basic Fibroblast Growth Factor (1-24) | PALPEDGGSGAFPPGHFKDPKRLY | ≥95.0% | 1mg | ￥360 |
| Brain Derived Basic Fibroblast Growth Factor (1-24) | PALPEDGGSGAFPPGHFKDPKRLY | ≥95.0% | 5mg | ￥1,080 |
| Brain Derived Acidic Fibroblast Growth Factor (102-111) | HAEKHWFVGL | ≥95.0% | 1mg | ￥150 |
| Brain Derived Acidic Fibroblast Growth Factor (102-111) | HAEKHWFVGL | ≥95.0% | 5mg | ￥450 |
| GTP-Binding Protein Fragment, Gs alpha | CKQLQKDKQVYRATHR | ≥95.0% | 1mg | ￥240 |
| GTP-Binding Protein Fragment, Gs alpha | CKQLQKDKQVYRATHR | ≥95.0% | 5mg | ￥720 |
| Histone H1-derived Peptide | GGGPATPKKAKKL | ≥95.0% | 1mg | ￥165 |
| Histone H1-derived Peptide | GGGPATPKKAKKL | ≥95.0% | 5mg | ￥495 |
| HIV-1 tat Protein (1-9) | MDPVDPNIE | ≥95.0% | 1mg | ￥135 |
| HIV-1 tat Protein (1-9) | MDPVDPNIE | ≥95.0% | 5mg | ￥405 |
| HIV-1 gag Protein p24 (194-210) | ANPDCKTILKALGPAAT | ≥95.0% | 1mg | ￥255 |
| HIV-1 gag Protein p24 (194-210) | ANPDCKTILKALGPAAT | ≥95.0% | 5mg | ￥765 |
| HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) | AVGIGALFLGFLGAAGSTMGARS-NH2 | ≥95.0% | 1mg | ￥378 |
| HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) | AVGIGALFLGFLGAAGSTMGARS-NH2 | ≥95.0% | 5mg | ￥1,134 |
| HIV (gp41) Fragment | AVGIGA | ≥95.0% | 1mg | ￥120 |
| HIV (gp41) Fragment | AVGIGA | ≥95.0% | 5mg | ￥360 |
| HIV (gp120) Fragment (318-327) | RGPGRAFVTI | ≥95.0% | 1mg | ￥150 |
| HIV (gp120) Fragment (318-327) | RGPGRAFVTI | ≥95.0% | 5mg | ￥450 |
| HIV-1 tat Protein (49-57) | RKKRRQRRR | ≥95.0% | 1mg | ￥135 |
| HIV-1 tat Protein (49-57) | RKKRRQRRR | ≥95.0% | 5mg | ￥405 |
| Laminin (925-933) | CDPGYIGSR | ≥95.0% | 1mg | ￥135 |
| Laminin (925-933) | CDPGYIGSR | ≥95.0% | 5mg | ￥405 |
| Laminin A Chain (2091-2108) | CSRARKQAASIKVAVSADR | ≥95.0% | 1mg | ￥270 |
| Laminin A Chain (2091-2108) | CSRARKQAASIKVAVSADR | ≥95.0% | 5mg | ￥810 |
| Laminin (929-933) | YIGSR | ≥95.0% | 1mg | ￥75 |
| Laminin (929-933) | YIGSR | ≥95.0% | 5mg | ￥225 |
| Laminin Penta Peptide, amide | YIGSR-NH2 | ≥95.0% | 1mg | ￥85 |
| Laminin Penta Peptide, amide | YIGSR-NH2 | ≥95.0% | 5mg | ￥255 |
| 名称 | 序列（一个字母） | 纯度 | 量 | ￥参考价 |
| Leptin (93-105), human | NVIQISNDLENLR | ≥95.0% | 1mg | ￥195 |
| Leptin (93-105), human | NVIQISNDLENLR | ≥95.0% | 5mg | ￥585 |
| Leptin (116-130), mouse | SCSLPQTSGLQKPES | ≥95.0% | 1mg | ￥225 |
| Leptin (116-130), mouse | SCSLPQTSGLQKPES | ≥95.0% | 5mg | ￥675 |
| Leucokinin I | DPAFNSWG | ≥95.0% | 1mg | ￥130 |
| Leucokinin I | DPAFNSWG | ≥95.0% | 5mg | ￥390 |
| [DTrp6]-LH-RH, amide | Glp-HWSY-DTrp-LRPG-NH2 | ≥95.0% | 1mg | ￥210 |
| [DTrp6]-LH-RH, amide | Glp-HWSY-DTrp-LRPG-NH2 | ≥95.0% | 5mg | ￥630 |
| LH-RH, Free Acid | Glp-HWSYGLRPG | ≥95.0% | 1mg | ￥165 |
| LH-RH, Free Acid | Glp-HWSYGLRPG | ≥95.0% | 5mg | ￥495 |
| LH-RH, human, Gonadoreline | Glp-HWSYGLRPG-NH2 | ≥95.0% | 1mg | ￥175 |
| LH-RH, human, Gonadoreline | Glp-HWSYGLRPG-NH2 | ≥95.0% | 5mg | ￥525 |
| LH-RH, salmon | Glp-HWSYGWLPG-NH2 | ≥95.0% | 1mg | ￥175 |
| LH-RH, salmon | Glp-HWSYGWLPG-NH2 | ≥95.0% | 5mg | ￥525 |
| LH-RH, lamprey | Glp-HYSLEWKPG-NH2 | ≥95.0% | 1mg | ￥175 |
| LH-RH, lamprey | Glp-HYSLEWKPG-NH2 | ≥95.0% | 5mg | ￥525 |
| Mast Cell Degranulating Peptide HR-1 | INLKAIAALVKKVL-NH2 | ≥95.0% | 1mg | ￥225 |
| Mast Cell Degranulating Peptide HR-1 | INLKAIAALVKKVL-NH2 | ≥95.0% | 5mg | ￥675 |
| Mast Cell Degranulating Peptide HR-2 | FLPLILGKLVKGLL-NH2 | ≥95.0% | 1mg | ￥225 |
| Mast Cell Degranulating Peptide HR-2 | FLPLILGKLVKGLL-NH2 | ≥95.0% | 5mg | ￥675 |
| Melanocyte-Stimulating Hormone-Release Inhibiting Factor | PLG-NH2 | ≥95.0% | 1mg | ￥55 |
| Melanocyte-Stimulating Hormone-Release Inhibiting Factor | PLG-NH2 | ≥95.0% | 5mg | ￥165 |
| MAGE-3 Antigen (167-176), human | MEVDPIGHLY | ≥95.0% | 1mg | ￥150 |
| MAGE-3 Antigen (167-176), human | MEVDPIGHLY | ≥95.0% | 5mg | ￥450 |
| MAGE-3 Antigen (271-279), human | FLWGPRALV | ≥95.0% | 1mg | ￥135 |
| MAGE-3 Antigen (271-279), human | FLWGPRALV | ≥95.0% | 5mg | ￥405 |
| Mage-1 Antigen (161-169), human | EADPTGHSY | ≥95.0% | 1mg | ￥135 |
| Mage-1 Antigen (161-169), human | EADPTGHSY | ≥95.0% | 5mg | ￥405 |
| (Met 210) Melanoctye Protein PMEL 17 (209-217) (human) | IMDQVPFSV | ≥95.0% | 1mg | ￥135 |
| (Met 210) Melanoctye Protein PMEL 17 (209-217) (human) | IMDQVPFSV | ≥95.0% | 5mg | ￥405 |
| Ile-Thr-Asp-Gln-Val-Pro-Phe-Ser-Val | ITDQVPFSV | ≥95.0% | 1mg | ￥135 |
| Ile-Thr-Asp-Gln-Val-Pro-Phe-Ser-Val | ITDQVPFSV | ≥95.0% | 5mg | ￥405 |
| Trp-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp | WNRQLYPEWTEAQRLD | ≥95.0% | 1mg | ￥240 |
| Trp-Asn-Arg-Gln-Leu-Tyr-Pro-Glu-Trp-Thr-Glu-Ala-Gln-Arg-Leu-Asp | WNRQLYPEWTEAQRLD | ≥95.0% | 5mg | ￥720 |
| Systemin | AVQSKPPSKRDPPKMQTD | ≥95.0% | 1mg | ￥270 |
| Systemin | AVQSKPPSKRDPPKMQTD | ≥95.0% | 5mg | ￥810 |
| Flag Peptide | DYKDDDDK | ≥95.0% | 1mg | ￥120 |
| Flag Peptide | DYKDDDDK | ≥95.0% | 5mg | ￥360 |
| OVA 323-339 | ISQAVHAAHAEINEAGR | ≥95.0% | 1mg | ￥272 |
| OVA 323-339 | ISQAVHAAHAEINEAGR | ≥95.0% | 5mg | ￥816 |
| OVA peptide (257-264) | SIINFEKL | ≥95.0% | 1mg | ￥120 |
| OVA peptide (257-264) | SIINFEKL | ≥95.0% | 5mg | ￥360 |
| Myelin Basic Protein (68-84), guinea pig | YGSLPQKSQRSQDEN | ≥95.0% | 1mg | ￥225 |
| Myelin Basic Protein (68-84), guinea pig | YGSLPQKSQRSQDEN | ≥95.0% | 5mg | ￥675 |
| Hexa His | HHHHHH | ≥95.0% | 1mg | ￥120 |
| Hexa His | HHHHHH | ≥95.0% | 5mg | ￥360 |
| MOG 35-55 | MEVGWYRSPFSRVVHLYRNGK | ≥95.0% | 1mg | ￥336 |
| MOG 35-55 | MEVGWYRSPFSRVVHLYRNGK | ≥95.0% | 5mg | ￥1,008 |
| Motilin, canine | FVPIFTHSELQKIREKERNKGQ | ≥95.0% | 1mg | ￥330 |
| Motilin, canine | FVPIFTHSELQKIREKERNKGQ | ≥95.0% | 5mg | ￥990 |
| Motilin, human, porcine | FVPIFTYGELQRMQEKERNKGQ | ≥95.0% | 1mg | ￥352 |
| Motilin, human, porcine | FVPIFTYGELQRMQEKERNKGQ | ≥95.0% | 5mg | ￥1,056 |
| Myelin Basic Protein (87-99) (human, bovine, rat) | VHFFKNIVTPRTP | ≥95.0% | 1mg | ￥195 |
| Myelin Basic Protein (87-99) (human, bovine, rat) | VHFFKNIVTPRTP | ≥95.0% | 5mg | ￥585 |
| Neurokinin B | DMHDFFVGLM-NH2 | ≥95.0% | 1mg | ￥165 |
| Neurokinin B | DMHDFFVGLM-NH2 | ≥95.0% | 5mg | ￥495 |
| Neurokinin A / Substance K | HKTDSFVGLM-NH2 | ≥95.0% | 1mg | ￥160 |
| Neurokinin A / Substance K | HKTDSFVGLM-NH2 | ≥95.0% | 5mg | ￥480 |
| Neuromedin C | GNHWAVGHLM-NH2 | ≥95.0% | 1mg | ￥160 |
| Neuromedin C | GNHWAVGHLM-NH2 | ≥95.0% | 5mg | ￥480 |
| Neuromedin B | GNLWATGHFM-NH2 | ≥95.0% | 1mg | ￥160 |
| Neuromedin B | GNLWATGHFM-NH2 | ≥95.0% | 5mg | ￥480 |
| Neuromedin N | KIPYIL | ≥95.0% | 1mg | ￥90 |
| Neuromedin N | KIPYIL | ≥95.0% | 5mg | ￥270 |
| Neuromedin (U25), human | FRVDEEFQSPFASQSRGYFLFRPRN-NH2 | ≥95.0% | 1mg | ￥400 |
| Neuromedin (U25), human | FRVDEEFQSPFASQSRGYFLFRPRN-NH2 | ≥95.0% | 5mg | ￥1,200 |
| Neuropeptide Y, human | YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 | ≥95.0% | 1mg | ￥664 |
| Neuropeptide Y, human | YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 | ≥95.0% | 5mg | ￥1,992 |
| Neuropeptide Y (13-36), human | PAEDMARYYSALRHYINLITRQRY-NH2 | ≥95.0% | 1mg | ￥360 |
| Neuropeptide Y (13-36), human | PAEDMARYYSALRHYINLITRQRY-NH2 | ≥95.0% | 5mg | ￥1,080 |
| Neuropeptide K, porcine | DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM-NH2 | ≥95.0% | 1mg | ￥598 |
| Neuropeptide K, porcine | DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM-NH2 | ≥95.0% | 5mg | ￥1,794 |
| Kassinin | DVPKSDQFVGLM-NH2 | ≥95.0% | 1mg | ￥195 |
| Kassinin | DVPKSDQFVGLM-NH2 | ≥95.0% | 5mg | ￥585 |
| Nocistatin | EQKQLQ | ≥95.0% | 1mg | ￥90 |
| Nocistatin | EQKQLQ | ≥95.0% | 5mg | ￥270 |
| Mastoparan | INLKALAALAKKIL-NH2 | ≥95.0% | 1mg | ￥220 |
| Mastoparan | INLKALAALAKKIL-NH2 | ≥95.0% | 5mg | ￥660 |
| Mastoparan X | INWKGIAAMAKKLL-NH2 | ≥95.0% | 1mg | ￥220 |
| Mastoparan X | INWKGIAAMAKKLL-NH2 | ≥95.0% | 5mg | ￥660 |
| Neuropeptide FF | FLFQPQRF-NH2 | ≥95.0% | 1mg | ￥130 |
| Neuropeptide FF | FLFQPQRF-NH2 | ≥95.0% | 5mg | ￥390 |
| Diazepam-Binding Inhibitor Fragment, human | QATVGDINTERPGMLDFTGK | ≥95.0% | 1mg | ￥320 |
| Diazepam-Binding Inhibitor Fragment, human | QATVGDINTERPGMLDFTGK | ≥95.0% | 5mg | ￥960 |
| Men 10376 | DY-DTrp-V-DTrp-DTrp-K-NH2 | ≥95.0% | 1mg | ￥205 |
| Men 10376 | DY-DTrp-V-DTrp-DTrp-K-NH2 | ≥95.0% | 5mg | ￥615 |
| Physalaemin | Glp-ADPNKFYGLM-NH2 | ≥95.0% | 1mg | ￥205 |
| Physalaemin | Glp-ADPNKFYGLM-NH2 | ≥95.0% | 5mg | ￥615 |
| Phyllomedusin | Glp-NPNRFIGLM-NH2 | ≥95.0% | 1mg | ￥190 |
| Phyllomedusin | Glp-NPNRFIGLM-NH2 | ≥95.0% | 5mg | ￥570 |
| Corazonin | Glp-TFQYSRGWTN-NH2 | ≥95.0% | 1mg | ￥205 |
| Corazonin | Glp-TFQYSRGWTN-NH2 | ≥95.0% | 5mg | ￥615 |
| Neurotensin (8-13) | RRPYIL | ≥95.0% | 1mg | ￥90 |
| Neurotensin (8-13) | RRPYIL | ≥95.0% | 5mg | ￥270 |
| Obestatin (human) | FNAPFDVGIKLSGVQYQQHSQAL-NH2 | ≥95.0% | 1mg | ￥378 |
| Obestatin (human) | FNAPFDVGIKLSGVQYQQHSQAL-NH2 | ≥95.0% | 5mg | ￥1,134 |
| Nociceptin / Orphanin FQ | FGGFTGARKSARKLANQ | ≥95.0% | 1mg | ￥254 |
| Nociceptin / Orphanin FQ | FGGFTGARKSARKLANQ | ≥95.0% | 5mg | ￥762 |
| Orexin B, canine | RPGPPGLQGRLQRLLQASGNHAAGILTM-NH2 | ≥95.0% | 1mg | ￥458 |
| Orexin B, canine | RPGPPGLQGRLQRLLQASGNHAAGILTM-NH2 | ≥95.0% | 5mg | ￥1,374 |
| Orexin B, human | RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2 | ≥95.0% | 1mg | ￥458 |
| Orexin B, human | RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2 | ≥95.0% | 5mg | ￥1,374 |
| PACAP (1-38), human, ovine, rat | HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 | ≥95.0% | 1mg | ￥684 |
| PACAP (1-38), human, ovine, rat | HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 | ≥95.0% | 5mg | ￥2,052 |
| PACAP-Related Peptide (PRP), rat | DVAHEILNEAYRKVLDQLSARKYLQSMVA | ≥95.0% | 1mg | ￥464 |
| PACAP-Related Peptide (PRP), rat | DVAHEILNEAYRKVLDQLSARKYLQSMVA | ≥95.0% | 5mg | ￥1,392 |
| PACAP-Related Peptide (PRP), human | DVAHGILNEAYRKVLDQLSAGKHLQSLVA | ≥95.0% | 1mg | ￥464 |
| PACAP-Related Peptide (PRP), human | DVAHGILNEAYRKVLDQLSAGKHLQSLVA | ≥95.0% | 5mg | ￥1,392 |
| PACAP (1-27), human, ovine, rat | HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2 | ≥95.0% | 1mg | ￥442 |
| PACAP (1-27), human, ovine, rat | HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2 | ≥95.0% | 5mg | ￥1,326 |
| PACAP (6-27), human, ovine, rat | FTDSYSRYRKQMAVKKYLAAVL-NH2 | ≥95.0% | 1mg | ￥362 |
| PACAP (6-27), human, ovine, rat | FTDSYSRYRKQMAVKKYLAAVL-NH2 | ≥95.0% | 5mg | ￥1,086 |
| Chromostatin, bovine | SDEDSDGDRPQASPGLGPGP | ≥95.0% | 1mg | ￥300 |
| Chromostatin, bovine | SDEDSDGDRPQASPGLGPGP | ≥95.0% | 5mg | ￥900 |
| Pancreatic Polypeptide (rat) | APLEPMYPGDYATHEQRAQYETQLRRYINTLTRPRY-NH2 | ≥95.0% | 1mg | ￥684 |
| Pancreatic Polypeptide (rat) | APLEPMYPGDYATHEQRAQYETQLRRYINTLTRPRY-NH2 | ≥95.0% | 5mg | ￥2,052 |
| Pancreatic Polypeptide (human) | APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 | ≥95.0% | 1mg | ￥684 |
| Pancreatic Polypeptide (human) | APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 | ≥95.0% | 5mg | ￥2,052 |
| Insulin B (9 - 23) | SHLVEALYLVCGERG | ≥95.0% | 1mg | ￥210 |
| Insulin B (9 - 23) | SHLVEALYLVCGERG | ≥95.0% | 5mg | ￥630 |
| PAR - 1 Agonist;Protease - Activated Receptor - 1 | TFLLRN | ≥95.0% | 1mg | ￥90 |
| PAR - 1 Agonist;Protease - Activated Receptor - 1 | TFLLRN | ≥95.0% | 5mg | ￥270 |
| PAR-4 (1-6) amide (human) | GYPGQV-NH2 | ≥95.0% | 1mg | ￥100 |
| PAR-4 (1-6) amide (human) | GYPGQV-NH2 | ≥95.0% | 5mg | ￥300 |
| PAR-4 (1-6) (human) | GYPGQV | ≥95.0% | 1mg | ￥90 |
| PAR-4 (1-6) (human) | GYPGQV | ≥95.0% | 5mg | ￥270 |
| PAR-4 (1-6) amide (mouse) | GYPGKF-NH2 | ≥95.0% | 1mg | ￥100 |
| PAR-4 (1-6) amide (mouse) | GYPGKF-NH2 | ≥95.0% | 5mg | ￥300 |
| PAR-4 (1-6) (mouse) | GYPGKF | ≥95.0% | 1mg | ￥90 |
| PAR-4 (1-6) (mouse) | GYPGKF | ≥95.0% | 5mg | ￥270 |
| P34cdc2 Kinase Substrate Peptide | ADAQHATPPKKKRKVEDPKDF | ≥95.0% | 1mg | ￥315 |
| P34cdc2 Kinase Substrate Peptide | ADAQHATPPKKKRKVEDPKDF | ≥95.0% | 5mg | ￥945 |
| Tyrosinase (206-214), human | AFLPWHRLF | ≥95.0% | 1mg | ￥136 |
| Tyrosinase (206-214), human | AFLPWHRLF | ≥95.0% | 5mg | ￥408 |
| Substrate for Tyrosine Protein Kinase | RRLIEDNEYTARG | ≥95.0% | 1mg | ￥194 |
| Substrate for Tyrosine Protein Kinase | RRLIEDNEYTARG | ≥95.0% | 5mg | ￥582 |
| S6-1 | RRLSSLRA | ≥95.0% | 1mg | ￥122 |
| S6-1 | RRLSSLRA | ≥95.0% | 5mg | ￥366 |
| Phosphate Acceptor Peptide | RRKASGPPV | ≥95.0% | 1mg | ￥136 |
| Phosphate Acceptor Peptide | RRKASGPPV | ≥95.0% | 5mg | ￥408 |
| Malantide | RTKRSGSVYEPLKI | ≥95.0% | 1mg | ￥210 |
| Malantide | RTKRSGSVYEPLKI | ≥95.0% | 5mg | ￥630 |
| QKRPSQRSKYL | QKRPSQRSKYL | ≥95.0% | 1mg | ￥150 |
| QKRPSQRSKYL | QKRPSQRSKYL | ≥95.0% | 5mg | ￥450 |
| Protease-Activated Receptor-2, PAR-2 Agonist, amide | SLIGKV-NH2 | ≥95.0% | 1mg | ￥110 |
| Protease-Activated Receptor-2, PAR-2 Agonist, amide | SLIGKV-NH2 | ≥95.0% | 5mg | ￥330 |
| Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 | ≥95.0% | 1mg | ￥426 |
| Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 | ≥95.0% | 5mg | ￥1,278 |
| Kemptide | LRRASLG | ≥95.0% | 1mg | ￥90 |
| Kemptide | LRRASLG | ≥95.0% | 5mg | ￥270 |
| Phosphorylase Kinase b-Subunit (420-436) | KRNPGSQKRFPSNCGRD | ≥95.0% | 1mg | ￥255 |
| Phosphorylase Kinase b-Subunit (420-436) | KRNPGSQKRFPSNCGRD | ≥95.0% | 5mg | ￥765 |
| Myosin Kinase Inhibiting Peptide | KKRAARATS-NH2 | ≥95.0% | 1mg | ￥145 |
| Myosin Kinase Inhibiting Peptide | KKRAARATS-NH2 | ≥95.0% | 5mg | ￥435 |
| Syntide 2 | PLARTLSVAGLPGKK | ≥95.0% | 1mg | ￥225 |
| Syntide 2 | PLARTLSVAGLPGKK | ≥95.0% | 5mg | ￥675 |
| Tyrosinase (192-200), human mouse | SEIWRDIDF | ≥95.0% | 1mg | ￥135 |
| Tyrosinase (192-200), human mouse | SEIWRDIDF | ≥95.0% | 5mg | ￥405 |
| Tyr-Ile-Tyr-Gly-Ser-Phe-Lys | YIYGSFK | ≥95.0% | 1mg | ￥105 |
| Tyr-Ile-Tyr-Gly-Ser-Phe-Lys | YIYGSFK | ≥95.0% | 5mg | ￥315 |
| Casein Kinase II Substrate | RRREEETEEE | ≥95.0% | 1mg | ￥210 |
| Casein Kinase II Substrate | RRREEETEEE | ≥95.0% | 5mg | ￥630 |
| RREEETEEE | RREEETEEE | ≥95.0% | 1mg | ￥189 |
| RREEETEEE | RREEETEEE | ≥95.0% | 5mg | ￥567 |
| Ser25] Protein Kinase C (19-31) | RFARKGSLRQKNV | ≥95.0% | 1mg | ￥195 |
| Ser25] Protein Kinase C (19-31) | RFARKGSLRQKNV | ≥95.0% | 5mg | ￥585 |
| [Ala9] Autocamtide 2 | KKALRRQEAVDAL | ≥95.0% | 1mg | ￥195 |
| [Ala9] Autocamtide 2 | KKALRRQEAVDAL | ≥95.0% | 5mg | ￥585 |
| Autocamtide 2 | KKALRRQETVDAL | ≥95.0% | 1mg | ￥195 |
| Autocamtide 2 | KKALRRQETVDAL | ≥95.0% | 5mg | ￥585 |
| cAMP Dependent PK Inhibitor (5-22), amide | TTYADFIASGRTGRRNAI-NH2 | ≥95.0% | 1mg | ￥280 |
| cAMP Dependent PK Inhibitor (5-22), amide | TTYADFIASGRTGRRNAI-NH2 | ≥95.0% | 5mg | ￥840 |
| RR-SRC | RRLIEDAEYAARG | ≥95.0% | 1mg | ￥195 |
| RR-SRC | RRLIEDAEYAARG | ≥95.0% | 5mg | ￥585 |
| Protein Kinase C (19-35) Peptide | RFARKGALRQKNVHEVK | ≥95.0% | 1mg | ￥255 |
| Protein Kinase C (19-35) Peptide | RFARKGALRQKNVHEVK | ≥95.0% | 5mg | ￥765 |
| Protein Kinase C (gamma) Peptide | NYPLELYERVRTGC | ≥95.0% | 1mg | ￥210 |
| Protein Kinase C (gamma) Peptide | NYPLELYERVRTGC | ≥95.0% | 5mg | ￥630 |
| 5FAM-RQMSFRL | 5FAM-RQMSFRL | ≥95.0% | 1mg | ￥276 |
| 5FAM-RQMSFRL | 5FAM-RQMSFRL | ≥95.0% | 5mg | ￥828 |
| 5FAM-RKRRQTSM | 5FAM-RKRRQTSM | ≥95.0% | 1mg | ￥294 |
| 5FAM-RKRRQTSM | 5FAM-RKRRQTSM | ≥95.0% | 5mg | ￥882 |
| 5FAM-RKRSRAEA-NH2 | 5FAM-RKRSRAEA-NH2 | ≥95.0% | 1mg | ￥304 |
| 5FAM-RKRSRAEA-NH2 | 5FAM-RKRSRAEA-NH2 | ≥95.0% | 5mg | ￥912 |
| 5FAM-RPRTSSF | 5FAM-RPRTSSF | ≥95.0% | 1mg | ￥276 |
| 5FAM-RPRTSSF | 5FAM-RPRTSSF | ≥95.0% | 5mg | ￥828 |
| 5FAM-RTKRSGSVYEPLKI-NH2 | 5FAM-RTKRSGSVYEPLKI-NH2 | ≥95.0% | 1mg | ￥420 |
| 5FAM-RTKRSGSVYEPLKI-NH2 | 5FAM-RTKRSGSVYEPLKI-NH2 | ≥95.0% | 5mg | ￥1,260 |
| 5FAM-NVKSKIGSTENLK-NH2 | 5FAM-NVKSKIGSTENLK-NH2 | ≥95.0% | 1mg | ￥402 |
| 5FAM-NVKSKIGSTENLK-NH2 | 5FAM-NVKSKIGSTENLK-NH2 | ≥95.0% | 5mg | ￥402 |
| 5FAM-DEEIYEELK-NH2 | 5FAM-DEEIYEELK-NH2 | ≥95.0% | 1mg | ￥322 |
| 5FAM-DEEIYEELK-NH2 | 5FAM-DEEIYEELK-NH2 | ≥95.0% | 5mg | ￥966 |
| 5FAM-QNPSRCSVSLSNVEA-NH2 | 5FAM-QNPSRCSVSLSNVEA-NH2 | ≥95.0% | 1mg | ￥438 |
| 5FAM-QNPSRCSVSLSNVEA-NH2 | 5FAM-QNPSRCSVSLSNVEA-NH2 | ≥95.0% | 5mg | ￥1,314 |
| 5FAM-ERRKSKSGA-NH2 | 5FAM-ERRKSKSGA-NH2 | ≥95.0% | 1mg | ￥312 |
| 5FAM-ERRKSKSGA-NH2 | 5FAM-ERRKSKSGA-NH2 | ≥95.0% | 5mg | ￥936 |
| Hypercalcemia Malignancy Factor (1-34), human | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA | ≥95.0% | 1mg | ￥578 |
| Hypercalcemia Malignancy Factor (1-34), human | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA | ≥95.0% | 5mg | ￥1,734 |
| Hypercalcemia Malignancy Factor (1-34), amide, human | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA-NH2 | ≥95.0% | 1mg | ￥588 |
| Hypercalcemia Malignancy Factor (1-34), amide, human | AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA-NH2 | ≥95.0% | 5mg | ￥1,764 |
| Parathyroid Hormone (1-34), rat | AVSEIQLMHNLGKHLASVERMQWLRKKLQDVHNF | ≥95.0% | 1mg | ￥578 |
| Parathyroid Hormone (1-34), rat | AVSEIQLMHNLGKHLASVERMQWLRKKLQDVHNF | ≥95.0% | 5mg | ￥1,734 |
| Parathyroid Hormone (1-34), bovine | AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNF | ≥95.0% | 1mg | ￥578 |
| Parathyroid Hormone (1-34), bovine | AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNF | ≥95.0% | 5mg | ￥1,734 |
| Angiotensinogen (1-14), human | DRVYIHPFHLVIHN | ≥95.0% | 1mg | ￥210 |
| Angiotensinogen (1-14), human | DRVYIHPFHLVIHN | ≥95.0% | 5mg | ￥630 |
| Acetyl Angiotensinogen (1-14), porcine | Ac-DRVYIHPFHLLVYS | ≥95.0% | 1mg | ￥220 |
| Acetyl Angiotensinogen (1-14), porcine | Ac-DRVYIHPFHLLVYS | ≥95.0% | 5mg | ￥660 |
| Acetyl, Angiotensinogen (1-14), human | Ac-DRVYIHPFHLVIHN | ≥95.0% | 1mg | ￥220 |
| Acetyl, Angiotensinogen (1-14), human | Ac-DRVYIHPFHLVIHN | ≥95.0% | 5mg | ￥660 |
| Renin Substrate Tetradecapeptide, rat | DRVYIHPFHLLYYS | ≥95.0% | 1mg | ￥210 |
| Renin Substrate Tetradecapeptide, rat | DRVYIHPFHLLYYS | ≥95.0% | 5mg | ￥630 |
| Angiotensinogen (1-14), porcine | DRVYIHPFHLLVYS | ≥95.0% | 1mg | ￥210 |
| Angiotensinogen (1-14), porcine | DRVYIHPFHLLVYS | ≥95.0% | 5mg | ￥630 |
| Angiotensinogen (1-13), human | DRVYIHPFHLVIH | ≥95.0% | 1mg | ￥195 |
| Angiotensinogen (1-13), human | DRVYIHPFHLVIH | ≥95.0% | 5mg | ￥585 |
| P-H-P-F-H-F-F-V-Y-K | PHPFHFFVYK | ≥95.0% | 1mg | ￥150 |
| P-H-P-F-H-F-F-V-Y-K | PHPFHFFVYK | ≥95.0% | 5mg | ￥450 |
| [Cys8] Renin Substrate Tetradecapeptide, rat | DRVYIHPCHLLYYS | ≥95.0% | 1mg | ￥210 |
| [Cys8] Renin Substrate Tetradecapeptide, rat | DRVYIHPCHLLYYS | ≥95.0% | 5mg | ￥630 |
| [Leu8] Renin Substrate Tetradecapeptide, rat | DRVYIHPLHLLYYS | ≥95.0% | 1mg | ￥210 |
| [Leu8] Renin Substrate Tetradecapeptide, rat | DRVYIHPLHLLYYS | ≥95.0% | 5mg | ￥630 |
| [Val8] Renin Substrate Tetradecapeptide, rat | DRVYIHPVHLLYYS | ≥95.0% | 1mg | ￥210 |
| [Val8] Renin Substrate Tetradecapeptide, rat | DRVYIHPVHLLYYS | ≥95.0% | 5mg | ￥630 |
| Secretin, rat | HSDGTFTSELSRLQDSARLQRLLQGLV-NH2 | ≥95.0% | 1mg | ￥417 |
| Secretin, rat | HSDGTFTSELSRLQDSARLQRLLQGLV-NH2 | ≥95.0% | 5mg | ￥1,251 |
| Secretin (5-27), porcine | TFTSELSRLRDSARLQRLLQGLV-NH2 | ≥95.0% | 1mg | ￥332 |
| Secretin (5-27), porcine | TFTSELSRLRDSARLQRLLQGLV-NH2 | ≥95.0% | 5mg | ￥996 |
| Secretin, human | HSDGTFTSELSRLREGARLQRLLQGLV-NH2 | ≥95.0% | 1mg | ￥442 |
| Secretin, human | HSDGTFTSELSRLREGARLQRLLQGLV-NH2 | ≥95.0% | 5mg | ￥1,362 |
| Selank | TKPRPGP | ≥98.0% | 1mg | ￥108 |
| Selank | TKPRPGP | ≥98.0% | 5mg | ￥324 |
| Somatostatin 28 (1-14) | SANSNPAMAPRERK | ≥95.0% | 1mg | ￥210 |
| Somatostatin 28 (1-14) | SANSNPAMAPRERK | ≥95.0% | 5mg | ￥630 |
| Somatostatin1-14 | AGCKNFFWKTFTSC (C3&C14 bridge) | ≥95.0% | 1mg | ￥320 |
| Somatostatin1-14 | AGCKNFFWKTFTSC (C3&C14 bridge) | ≥95.0% | 5mg | ￥960 |
| RC-160 (Vapreotide) | fCYwKVCW-NH2 (C2&C7 bridge) | ≥95.0% | 1mg | ￥300 |
| RC-160 (Vapreotide) | fCYwKVCW-NH2 (C2&C7 bridge) | ≥95.0% | 5mg | ￥900 |
| NTB (Naltriben) | DPhe-CY-DTrp-Orn-T-Pen-T-NH2(Cys2&Pen7 bridge) | ≥95.0% | 1mg | ￥300 |
| NTB (Naltriben) | DPhe-CY-DTrp-Orn-T-Pen-T-NH2(Cys2&Pen7 bridge) | ≥95.0% | 5mg | ￥900 |
| [DPro2,DPhe7,DTrp9] Substance P | R-DPro-KPQQ-DPhe-F-DTrp-LM-NH2 | ≥95.0% | 1mg | ￥265 |
| [DPro2,DPhe7,DTrp9] Substance P | R-DPro-KPQQ-DPhe-F-DTrp-LM-NH2 | ≥95.0% | 5mg | ￥795 |
| MG-132 | RPKPQQFFGLM-NH2 | ≥95.0% | 1mg | ￥175 |
| MG-132 | RPKPQQFFGLM-NH2 | ≥95.0% | 5mg | ￥525 |
| Pep-1 | KETWWETWWTEWSQPKKKRKV | ≥95.0% | 1mg | ￥336 |
| Pep-1 | KETWWETWWTEWSQPKKKRKV | ≥95.0% | 5mg | ￥1,008 |
| HIV-1 TAT Protein Peptide | YGRKKRRQRRR | ≥95.0% | 1mg | ￥165 |
| HIV-1 TAT Protein Peptide | YGRKKRRQRRR | ≥95.0% | 5mg | ￥495 |
| TAT 2-4 | YGRKKRRQRRRGYGRKKRRQRRRG | ≥95.0% | 1mg | ￥384 |
| TAT 2-4 | YGRKKRRQRRRGYGRKKRRQRRRG | ≥95.0% | 5mg | ￥1,152 |
| Scrambled TRAP Fragment | FSLLRN-NH2 | ≥95.0% | 1mg | ￥102 |
| Scrambled TRAP Fragment | FSLLRN-NH2 | ≥95.0% | 5mg | ￥306 |
| Hemoglobin (Hb) (64-76) | GKKVITAFNEGLK | ≥95.0% | 1mg | ￥195 |
| Hemoglobin (Hb) (64-76) | GKKVITAFNEGLK | ≥95.0% | 5mg | ￥585 |
| Thymopoietin II (32-34) | RKD | ≥95.0% | 1mg | ￥60 |
| Thymopoietin II (32-34) | RKD | ≥95.0% | 5mg | ￥180 |
| Thymopoietin II (32-35) | RKDV | ≥95.0% | 1mg | ￥80 |
| Thymopoietin II (32-35) | RKDV | ≥95.0% | 5mg | ￥240 |
| Thymopentin | RKDVY | ≥95.0% | 1mg | ￥80 |
| Thymopentin | RKDVY | ≥95.0% | 5mg | ￥240 |
| Urocortin II, human | IVLSLDVPIGLLQILLEQARARAAREQATTNARILARVGHC-NH2 | ≥95.0% | 1mg | ￥748 |
| Urocortin II, human | IVLSLDVPIGLLQILLEQARARAAREQATTNARILARVGHC-NH2 | ≥95.0% | 5mg | ￥2,244 |
| Urocortin III, mouse | FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI-NH2 | ≥95.0% | 1mg | ￥694 |
| Urocortin III, mouse | FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI-NH2 | ≥95.0% | 5mg | ￥2,082 |
| Urocortin III, human | FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI-NH2 | ≥95.0% | 1mg | ￥694 |
| Urocortin III, human | FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI-NH2 | ≥95.0% | 5mg | ￥2,082 |
| Urocortin, human | DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 | ≥95.0% | 1mg | ￥735 |
| Urocortin, human | DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 | ≥95.0% | 5mg | ￥2,205 |
| Urocortin, rat | DDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 | ≥95.0% | 1mg | ￥735 |
| Urocortin, rat | DDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 | ≥95.0% | 5mg | ￥2,205 |
| Urocortin III, mouse, free acid | FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI | ≥95.0% | 1mg | ￥684 |
| Urocortin III, mouse, free acid | FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI | ≥95.0% | 5mg | ￥2,052 |
| Urotensin I | NDDPPISIDLTFHLLRNMIEMARIENEREQAGLNRKYLDEV-NH2 | ≥95.0% | 1mg | ￥738 |
| Urotensin I | NDDPPISIDLTFHLLRNMIEMARIENEREQAGLNRKYLDEV-NH2 | ≥95.0% | 5mg | ￥2,214 |
| VIP, human, porcine, rat, ovine | HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2 | ≥95.0% | 1mg | ￥486 |
| VIP, human, porcine, rat, ovine | HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2 | ≥95.0% | 5mg | ￥1,458 |
| PHI, rat | HADGVFTSDYSRLLGQISAKKYLESLI-NH2 | ≥95.0% | 1mg | ￥469 |
| PHI, rat | HADGVFTSDYSRLLGQISAKKYLESLI-NH2 | ≥95.0% | 5mg | ￥1,407 |
| VIP, guinea pig | HSDALFTDTYTRLRKQMAMKKYLNSVLN-NH2 | ≥95.0% | 1mg | ￥458 |
| VIP, guinea pig | HSDALFTDTYTRLRKQMAMKKYLNSVLN-NH2 | ≥95.0% | 5mg | ￥1,374 |
| Peptide T | ASTTTNYT | ≥95.0% | 1mg | ￥120 |
| Peptide T | ASTTTNYT | ≥95.0% | 5mg | ￥360 |
| R15K, HIV-1 Inhibitory Peptide | RIQRGPGRAFVTIGK | ≥95.0% | 1mg | ￥225 |
| R15K, HIV-1 Inhibitory Peptide | RIQRGPGRAFVTIGK | ≥95.0% | 5mg | ￥675 |